New Data Across the Chronic Urticaria Continuum

New poster data can do more than add another number to the literature; they can sharpen what clinicians notice in practice. This experience brings together two analyses across chronic urticaria, exploring procedural safety with remibrutinib in CSU alongside real-world disease control across CIndU subtypes. Through focused short-form video, the findings are placed back into the clinical context where they matter most: treatment decisions, follow-up, and the everyday work of defining meaningful control.